Novel natural killer cell-based therapies for hematologic and solid malignancies: latest updates from ASCO 2024

IF 29.5 1区医学 Q1 HEMATOLOGY

Journal of Hematology & Oncology Pub Date : 2024-07-29 DOI:10.1186/s13045-024-01575-0

Xubo Gong, Lianjun Zhang, Xin He, Jing Yang, Xiang Li, Weiwei Liu, Bin Zhang, Zhihua Tao, Wenbin Qian

引用次数: 0

Abstract

Natural killer (NK) cell-based therapies have made great progress in treating both hematological and solid tumors. Their unique mechanism of action does not rely on antigen presentation to recognize and eliminate tumor cells, making them a promising approach for cancer immunotherapy. In this review, we present a comprehensive summary of the latest clinical data of the novel NK cell-based therapies from the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, highlighting the potential of these advancements to revolutionize the treatment of hematologic malignancies and solid tumors.

查看原文本刊更多论文

基于自然杀伤细胞的新型血液和实体恶性肿瘤疗法：ASCO 2024 的最新进展

基于自然杀伤（NK）细胞的疗法在治疗血液肿瘤和实体瘤方面都取得了巨大进展。它们独特的作用机制不依赖于抗原递呈来识别和消除肿瘤细胞，使其成为一种前景广阔的癌症免疫疗法。在这篇综述中，我们全面总结了 2024 年美国临床肿瘤学会（ASCO）年会上基于 NK 细胞的新型疗法的最新临床数据，强调了这些进展在彻底改变血液恶性肿瘤和实体瘤治疗方面的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Hematology & Oncology 医学-血液学

CiteScore

48.10

自引率

2.10%

发文量

169

审稿时长

6-12 weeks

期刊介绍： The Journal of Hematology & Oncology, an open-access journal, publishes high-quality research covering all aspects of hematology and oncology, including reviews and research highlights on "hot topics" by leading experts. Given the close relationship and rapid evolution of hematology and oncology, the journal aims to meet the demand for a dedicated platform for publishing discoveries from both fields. It serves as an international platform for sharing laboratory and clinical findings among laboratory scientists, physician scientists, hematologists, and oncologists in an open-access format. With a rapid turnaround time from submission to publication, the journal facilitates real-time sharing of knowledge and new successes.